Patents by Inventor Laurie Shekels

Laurie Shekels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mucin Derived Polypeptides
    Publication number: 20170008940
    Abstract: The present technology relates to isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same. The MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides can be used to treat gastrointestinal tract diseases and disorders. Also described herein are pharmaceutical compositions comprising MUC17, Muc3 or MUC3 derived polypeptides and/or polynucleotides encoding the same alone or in combination along with a pharmaceutically acceptable carrier, diluent or excipient for the treatment of gastrointestinal disorders and diseases, including, irritable bowel disease and its associated colitides, for example, Crohn's Disease.
    Type: Application
    Filed: July 23, 2015
    Publication date: January 12, 2017
    Inventors: Ronald J. Shebuski, Samuel B. Ho, Laurie Shekels, Robert L. Heinrikson
  • Mucin derived polypeptides
    Patent number: 9119869
    Abstract: Isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same are described. The MUC17, Muc3 or MUC3 derived polypeptides, polynucleotides, and pharmaceutical compositions can be used to treat gastrointestinal tract diseases and disorders including, inflammatory bowel disease and its associated colitides, for example, Crohn's Disease.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: September 1, 2015
    Inventors: Ronald J. Shebuski, Samuel B. Ho, Laurie Shekels, Robert L. Heinrikson
  • Mucin Derived Polypeptides
    Publication number: 20120028911
    Abstract: The present technology relates to isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same. The MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides can be used to treat gastrointestinal tract diseases and disorders. Also described herein are pharmaceutical compositions comprising MUC17, Muc3 or MUC3 derived polypeptides and/or polynucleotides encoding the same alone or in combination along with a pharmaceutically acceptable carrier, diluent or excipient for the treatment of gastrointestinal disorders and diseases, including, irritable bowel disease and its associated colitides, for example, Crohn's Disease.
    Type: Application
    Filed: April 29, 2011
    Publication date: February 2, 2012
    Applicant: MuciMed, Inc.
    Inventors: Ronald J. Shebuski, Samuel B. Ho, Laurie Shekels, Robert L. Heinrikson